Institutional Biosafety Committee Meeting
9/14/2026
10:00am via Zoom
Virtual Meeting

Institutional Biosafety Committee Meeting minutes

Meeting Attendance:

- Members in attendance:
  - Elena Demireva
  - Jamie Willard-Smith
  - Dave Morgan
  - Andras Komaromy
  - Guo-Qing Song
  - Carolina de Aguiar Ferreira
  - Michael Bachmann
  - Jonathan Hardy
  - Raj Kulkarni

- Members not in attendance:
  - Jan Patterson Samson
  - Carrie Anglewicz

- Others in attendance:
  - Sarah Roosa
  - Alessandra Hunt
  - Luis Ochoa Carrera

Call to order:

  - Elena Demireva

Roll call:

  - Sarah Roosa

Discussion of the agenda:

- Approved

Discussion of minutes:

- Approved

Institutional Biosafety Committee Meeting

9/14/2026
10:00am via Zoom
Virtual Meeting

Registration review:

Study Info

SAFETY0001511: [redacted]

Investigating dendritic cell dysfunction and immune tolerance during tumor progression

Training: Complete for all members listed

NIH III-D, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following

- Biosafety Summary
  - 2: Will tamoxifen be used only in animals? Or will it be used in cell lines as well? Will any other drugs be use in this project, e.g. are any of the listed inhibitors small molecules or drugs?
- Recombinant or Synthetic Nucleic Acids Usage
  - 3a: Provide additional details on working with OT1 and OT2 transgenic mice
  - 3c. If any knockdowns or knockouts of tumor suppressor genes are used, list here.
- Recombinant or Synthetic Nucleic Acid Work Description
  - 4: Select Yes, if using VSV or other pseudotyping of viral vectors
  - 5: Provide host range, pathogenicity
  - 6: Provide genus, species and strain for lentivirus
- Exposure Assessment and Protective Equipment
  - 4: The committee recommends replacing glass Pasteur pipettes with plastic alternatives if using for tissue culture activities
- Supporting Documents
  - Are any sharps being used with infections or human materials (i.e. glass pipettes on human cell tissue culture?) If so, please include them in the safter sharps documents. If no sharps are being used on human materials the sharps documents can be removed.

Study Info

SAFETY0001514: [redacted]

Adenoviral Cre administration in mouse models of cancer

Training: Complete for all members listed

NIH III-D, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following

- BioSafety Summary
  - Please provide more information about the ULK-101 treatment. What does ULK-101 do? Is any toxicity associated with ULK-101?
- Recombinant or Synthetic Nucleic Acid Work Description
  - 6a: Select Yes and provide details for adenovirus.

- Exposure Assessment and Protective Equipment
  - 1: Remove “Our system uses a single administration of the virus, which significantly limits the opportunity for human exposure and inducing an immune response.”
  - 5: Add bleach at 10% concentration for 10 minutes for decontamination when using virus
- Waste Management/Environmental Release Controls
  - 1: Will you have liquid waste to decontaminate? If so, select the liquid waste option and indicate the decontamination method (10% Bleach for 10 min)

Study Info

SAFETY0001519: [redacted]
Intravital imaging of mice
Training: Complete for all members listed
BMR, RG-1, BSL-2
This registration has been approved with edits. The PI has been asked to clarify the following

- Basic Info
  - 3: Please add more details about the rational for the research, the primary objectives and processes used.
- Tissues, Blood, or Body Fluids
  - 3: Select No as these cells are covered in the Human Primary Cells or Cell Lines section.
- Human Primary Cells or Cell Lines
  - 5e. Upload the MSU Flow Cytometry Core Facility Cell Sorting Addendum here and remove from Supporting Documents.

Study Info

SAFETY0001521: [redacted]
AAV Mediated Knockdown in Rodents
Training: Complete for all members listed
NIH III-D, RG-2, BSL-2
This registration has been approved with edits. The PI has been asked to clarify the following

Institutional Biosafety Committee Meeting

9/14/2026
10:00am via Zoom
Virtual Meeting

- Recombinant or Synthetic Nucleic Acid Work Description
  - 6: Add genus and species for AAV
- Risk Group and Containment Practices
  - 1: Change to RG-1

Study Info

SAFETY0001523: [redacted]
[redacted]Lab Safety Protocol
Training: Complete for all members listed
NIH III-D, RG-1, BSL-1
This registration has been approved with edits. The PI has been asked to clarify the following

- Recombinant or Synthetic Nucleic Acids Usage
  - 3b: Ensure accuracy of source for all inserts in AAV stock document
  - 3b: Add bioactivity for all inserts in AAV stock document
- Exposure Assessment and Protective Equipment
  - 1: Change statement "In the absence of a helper virus, AAV can stably integrate into the host cell genome." This is true for WT virus but not in all cases, however, there is a much lower frequency with replication-incompetent virus.
  - 3: Add Centrifuge with aerosol containment (including sealed safety cups, safety buckets, or sealed rotors)
- Supporting Documents
  - Add sharps if using with infectious materials

Study Info

SAFETY0001525: [redacted]
Genomic and phenotypic characterization of Listeria monocytogenes
Training: Complete for all members listed
NIH III-D, RG-2, BSL-2
No vote at this meeting. Committee needs to review the new Guidelines before discussion and vote.

Institutional Biosafety Committee Meeting

9/14/2026
10:00am via Zoom
Virtual Meeting

- Waste Management/Environmental Release Controls
    - 1: Will you use Chemical treatment of liquid waste prior to sewer? If so, select that option and add chemical disinfectant details (10% Bleach for 10 min)
- The new "USG-Policy-for-Stopping-High-Risk-Life-Sciences-Research" will be sent to Dr. [redacted] and the IBC members
- Ad Hoc after Guideline review
    - Elena
    - Jonathan
    - Michael
    - Carrie

New Items:

- Discussion of Request for Comment: Draft NIH Biosafety Policy for Research Involving Biohazards
    - Information on the new Guidelines to be sent to all IBC members
- Vote on Rhia LeVeque as new lab technician IBC member.
    - 8 yes
    - 0 no
    - 3 abstain
- Rhia LeVeque will be contacted for IBC onboarding
- Contact CLICK helpdesk about changing the language in Recombinant or Synthetic Nucleic Acids Usage question 3 to "Are you using recombinant or synthetic nucleic acid molecules?"
    - Replace "inserts" with "molecules" in 3a, 3c, and 3e.

Previous Submissions:

- SAFETY0001211 [redacted]
- SAFETY0001500 [redacted]

Next Meeting:

- Wednesday October 21, 2026 at 10:30am